- Home
- BANC vs TARS Comparison
BANC vs TARS Comparison
Compare BANC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANC | TARS |
|---|---|---|
| Founded | 1941 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BANC | TARS |
|---|---|---|
| Price | $18.16 | $74.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $21.83 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.2M | 651.6K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 125.00 | 48.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,818,792,000.00 | $451,360,000.00 |
| Revenue This Year | $13.93 | $56.43 |
| Revenue Next Year | $8.03 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $15.33 | $48.20 |
| 52 Week High | $21.93 | $85.25 |
Technical Indicators
Market Signals| Indicator | BANC | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 66.06 |
| Support Level | $17.80 | $60.32 |
| Resistance Level | $19.40 | $79.10 |
| Average True Range (ATR) | 0.35 | 2.29 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 1.93 | 83.94 |
Price Performance
Historical ComparisonAbout BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.